The reiteration of a Buy rating and maintenance of a $97 price target by a reputable analyst like Ami Fadia from Needham is a strong positive signal for Blueprint Medicines. This endorsement likely reflects confidence in the company's future performance and growth prospects, which could positively influence investor sentiment and potentially drive the stock price up in the short term.